Breast Cancer Clinical Trials in Massachusetts

Showing 21-40 of 599 trials

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

NCT04468061

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * Sacituzumab govitecan (Trodelvy™;IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)

Breast CancerTriple Negative Breast CancerPD-L1 Negative

Dana-Farber Cancer Institute110 participantsStarted Jul 2020

Stamford, Connecticut, United States • Miami, Florida, United States • Plantation, Florida, United States +12 more locations

Active Not RecruitingPhase 326 miles

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Locally Advanced (Inoperable) or Metastatic Breast Cancer

AstraZeneca818 participantsStarted Apr 2020

Gilbert, Arizona, United States • Orange, California, United States • San Francisco, California, United States +212 more locations

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Breast Cancer Trials in Other Cities

Remote Monitoring and Symptom Management Digital Application

Exercise in Metastatic Breast Cancer: EMBody

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

The PREDICT Registry:

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Other Conditions in Massachusetts